| Characteristic | Result | p-value |
| Sex | 0.192 | |
| Male | 113 (65) | |
| Female | 62 (35) | |
| Race | 0.066 | |
| Caucasian | 162 (93) | |
| African-American | 13 (7) | |
| Age at diagnosis yrs | 66 (58–72) | 0.041 |
| ≤60 | 61 (35) | 0.031 |
| >60 | 114 (65) | |
| Smoking status | ||
| Current smoker | 59 (34) | 0.61 |
| Ex-smoker | 104 (60) | |
| Never-smoker | 10 (6) | |
| Smoking history pack-yrs | 50 (30–80) | 0.086 |
| DL,CO % pred | 76 (57–96) | 0.976 |
| FEV1 % pred | 68 (54–85) | 0.703 |
| Lung cancer histology | <0.0001 | |
| ADC | 98 (56) | |
| SCC | 67 (38) | |
| Undifferentiated NSCLC | 10 (6) | |
| Pathological stage | 0.151 | |
| I | 102 (58) | |
| II | 19 (11) | |
| III | 35 (20) | |
| IV | 19 (11) | |
| Pathological tumour stage | 0.460 | |
| T1 | 68 (40) | |
| T2 | 63 (37) | |
| T3 | 18 (11) | |
| T4 | 22 (13) | |
| Pathological node stage | 0.095 | |
| N0 | 132 (78) | |
| N1 | 12 (7) | |
| N2 | 26 (15) | |
| Pathological metastasis stage | 0.332 | |
| M0 | 156 (89) | |
| M1 | 19 (11) | |
| R/P-free survival yrs | ||
| Median (95% CI) | 4 (2.6–6.8) | 0.411 |
| R/P-free at 3 yrs | 109 (63) | 0.580 |
| Overall survival yrs | ||
| Median (95% CI) | 3 (2.4–4.5) | 0.484 |
| Alive at 3 yrs | 90 (51) | 0.978 |
| Average pIgR staining score | ||
| 0 | 121 (69) | |
| ≥20 | 41 (23) | |
| ≥50 | 27 (15) | |
| ≥100 | 12 (7) |
Data are presented as n (%) or median (interquartile range), unless otherwise stated. DL,CO: diffusing capacity of the lung for carbon monoxide; % pred: % predicted; FEV1: forced expiratory volume in 1 s; ADC: adenocarcinoma; SCC: squamous cell carcinoma; NSCLC: nonsmall cell lung cancer; R recurrence; P: progression. Bold indicates statistically significant p-values.